Panelists discuss how upcoming studies at ASCO 2025 could change practice in kidney, bladder, and prostate cancer, highlighting research on novel drug combinations, biomarkers, organ-sparing approaches, and AI-driven treatment selection.
Outpatient Robotic Partial Nephrectomy Is Safe/Feasible for Renal Tumors
A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.
Leveraging Artificial Intelligence to Bolster Equitable Cancer Care
Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.
Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC
Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.
A Sneak Peek at 2025 ASCO From the GU Perspective
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.
Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC
Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.
Belzutifan Receives European Approval in Localized/Advanced RCC Indications
LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.